Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Praxis Precision Medicines (NASDAQ: PRAX) announced it will report financial results for the second quarter ended June 30, 2026, and provide a corporate update before markets open on Thursday, August 6, 2026.
Rhea-AI Summary
Praxis Precision Medicines (NASDAQ: PRAX) announced it will report financial results for the second quarter ended June 30, 2026, and provide a corporate update before markets open on Thursday, August 6, 2026.
The company will host a conference call and live webcast on August 6, 2026 at 8:30 a.m. ET to review the quarter and discuss corporate developments. Investors can access the live webcast via a registration link and through the Events & Presentations page in the Investors + Media section of www.praxismedicines.com. A replay of the second quarter earnings webcast will be available on the Events & Presentations page for approximately 90 days following the event.
Positive
- None.
Negative
- None.
Details
News Market Reaction – PRAX
In the Jul 31 session, PRAX gained 0.03%, reflecting a mild positive market reaction. Argus tracked a peak move of +2.6% during that session. Argus tracked a trough of -3.2% from its starting point during tracking. Our momentum scanner triggered 39 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Announcement date
- July 30, 2026
- News publication date
- Reporting period end
- June 30, 2026
- Second quarter 2026
- Results date
- Thursday, August 6, 2026
- Scheduled financial results release
- Conference call time
- 8:30 am ET
- Thursday, August 6, 2026
- Webcast replay availability
- Approximately 90 days
- After the second quarter earnings webcast
Historical Context
-
Entered research collaboration and license agreement for a transdermal ulixacaltamide patch.
-
Granted restricted stock units to new non-executive employees under inducement plan.
-
FDA extended relutrigine review after major amendment and additional sensitivity analyses.
-
Received FDA Breakthrough Therapy Designation supported by positive pediatric trial results.
-
Scheduled corporate presentation at annual global healthcare conference.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, July 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the second quarter ended June 30, 2026 and provide a corporate update, before the financial markets open on Thursday, August 6, 2026.
The Company will host a conference call and a live webcast to review the second quarter financial results and provide a corporate update on Thursday, August 6, 2026, at 8:30 am ET, which can be accessed by visiting this registration link. The live webcast will also be available through the Events & Presentations page of the Investors + Media section of the company’s website www.praxismedicines.com.
A replay of the second quarter earnings webcast will be available on Praxis’ Events & Presentations page of the company’s website after each event for approximately 90 days.
About Praxis
Praxis Precision Medicines is a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, Instagram, LinkedIn and Twitter/X.
Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry LifeSci Advisors Daniel@lifesciadvisors.com 617-430-7576
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.